|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 2 | A model to predict survival in patients with end-stage liver disease显示文摘 | Patrick S. Kamath Russell H. Wiesner Michael Malinchoc Walter Kremers Terry M. Therneau Catherine L. Kosberg Gennaro D’Amico E.Rolland Dickson W.Ray Kim | 2001 | Hepatology2001，，2： | 10 |
| 3 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 4 | Evidence-Based Incorporation of Serum Sodium Concentration Into MELD显示文摘 | Scott W. Biggins W. Ray Kim Norah A. Terrault Sammy Saab Vijay Balan Thomas Schiano Joanne Benson Terry Therneau Walter Kremers Russell Wiesner Patrick Kamath Goran Klintmalm | 2006 | Gastroenterology2006，，6： | 3 |
| 5 | A model to predict survival in patients with end-stage liver disease显示文摘 | Patrick S. Kamath Russell H. Wiesner Michael Malinchoc Walter Kremers Terry M. Therneau Catherine L. Kosberg Gennaro D'Amico E.Rolland Dickson W.Ray Kim | 2001 | Hepatology2001，，2： | 2 |
| 6 | Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes显示文摘 | Xiaodan Zhang William S. Harmsen Teresa A. Mettler W. Ray Kim Rosebud O. Roberts Terry M. Therneau Lewis R. Roberts Roongruedee Chaiteerakij | 2014 | Hepatology2014，，6： | 2 |
| 7 | Serum sodium, renal function, and survival of patients with end-stage liver disease显示文摘 | Young-Suk Lim Timothy S. Larson Joanne T. Benson Patrick S. Kamath Walter K. Kremers Terry M. Therneau W. Ray Kim | 2010 | Journal of Hepatology2010，，4： | 2 |
| 8 | Review of 1027 Patients With Newly Diagnosed Multiple Myeloma显示文摘 | Robert A. Kyle Morie A. Gertz Thomas E. Witzig John A. Lust Martha Q. Lacy Angela Dispenzieri Rafael Fonseca S. Vincent Rajkumar Janice R. Offord Dirk R. Larson Matthew E. Plevak Terry M. Therneau Philip R. Greipp | 2003 | Mayo Clinic Proceedings2003，，1： | 2 |
| 9 | Nonalcoholic fatty liver disease is associated with coronary artery calcification显示文摘 | Donghee Kim Su‐Yeon Choi Eun Ha Park Whal Lee Jin Hwa Kang Won Kim Yoon Jun Kim Jung‐Hwan Yoon Sook Hyang Jeong Dong Ho Lee Hyo‐suk Lee Joseph Larson Terry M. Therneau W. Ray Kim | 2012 | Hepatology2012，，2： | 2 |
| 10 | Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma显示文摘 | Ju Dong Yang W. Ray Kim Ritika Coelho Teresa A. Mettler Joanne T. Benson Schuyler O. Sanderson Terry M. Therneau Bohyun Kim Lewis R. Roberts | 2011 | Clinical Gastroenterology and Hepatology2011，，1： | 2 |
| 11 | Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance显示文摘 | Rajkumar S V Kyle R A Therneau T M | 2005 | Blood2005，106，3： | 1 |
| 12 | Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance显示文摘 | Rajkumar SV Kyle RA Therneau TM | 2005 | Blood2005，106，3： | 1 |
| 13 | Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades 显示文摘 | Kyle R A Therneau T M Rajkumar S V | 2004 | Cancer2004，101，26： | 1 |
| 14 | Clinical course and prognosis of smoldering(asymptomatic)multiple myeloma显示文摘 | Kyle RA Remstein ED Therneau TM | 2007 | N Engl J Med2007，356，： | 1 |
| 15 | Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma 显示文摘 | Kyle R A Remstein E Therneau T M | 2007 | New Engl J Med2007，356，25： | 1 |
| 16 | Brief report:accelerated aging influences cardiovascular disease risk in rheumatoid arthritis显示文摘 | Crowson CS Therneau TM Davis JM 3rd | 2013 | Arthritis Rheum2013，65，： | 1 |
| 17 | Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance 显示文摘 | Rajkumar SV Kyle RA Therneau TM | 2005 | Blood2005，106，： | 1 |
| 18 | Long- term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis 显示文摘 | Batts KP Therneau TM | 1999 | Hepatology1999，29，3： | 1 |
| 19 | Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma显示文摘 | Ju Dong Yang W. Ray Kim Ritika Coelho Teresa A. Mettler Joanne T. Benson Schuyler O. Sanderson Terry M. Therneau Bohyun Kim Lewis R. Roberts | 2011 | Clinical Gastroenterology and Hepatology2011，，1： | 1 |
| 20 | Disease associations with monoclonal gammopathy of undetermined significance~ a population-based study of 17,398 patients 显示文摘 | Bida JP Kyle RA Therneau TM | 2009 | Mayo Clin Proc2009，84，68： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员